Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Artiva Biotherapeutics, Inc. Common Stock (ARTV)ARTV

Upturn stock ratingUpturn stock rating
Artiva Biotherapeutics, Inc. Common Stock
$11.19
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -19.34%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 17
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/04/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -19.34%
Avg. Invested days: 17
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 260.36M USD
Price to earnings Ratio -
1Y Target Price 21.25
Dividends yield (FY) -
Basic EPS (TTM) -0.93
Volume (30-day avg) 93098
Beta -
52 Weeks Range 9.68 - 17.31
Updated Date 11/3/2024
Company Size Small-Cap Stock
Market Capitalization 260.36M USD
Price to earnings Ratio -
1Y Target Price 21.25
Dividends yield (FY) -
Basic EPS (TTM) -0.93
Volume (30-day avg) 93098
Beta -
52 Weeks Range 9.68 - 17.31
Updated Date 11/3/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -111.17%
Operating Margin (TTM) -108.84%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -44.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 229567183
Price to Sales(TTM) 8.9
Enterprise Value to Revenue 6.8
Enterprise Value to EBITDA -
Shares Outstanding 24287100
Shares Floating 4022194
Percent Insiders 20.64
Percent Institutions 74.78
Trailing PE -
Forward PE -
Enterprise Value 229567183
Price to Sales(TTM) 8.9
Enterprise Value to Revenue 6.8
Enterprise Value to EBITDA -
Shares Outstanding 24287100
Shares Floating 4022194
Percent Insiders 20.64
Percent Institutions 74.78

Analyst Ratings

Rating 4.8
Target Price 21.25
Buy 1
Strong Buy 4
Hold -
Sell -
Strong Sell -
Rating 4.8
Target Price 21.25
Buy 1
Strong Buy 4
Hold -
Sell -
Strong Sell -

About Artiva Biotherapeutics, Inc. Common Stock

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2024-07-19 President, CEO & Director Dr. Fred Aslan M.D.
Sector Healthcare Website https://www.artivabio.com
Industry Biotechnology Full time employees 82
Headquaters San Diego, CA, United States
President, CEO & Director Dr. Fred Aslan M.D.
Website https://www.artivabio.com
Website https://www.artivabio.com
Full time employees 82

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​